Burcak Beser - Oncotelic Therapeutics CTO Division
Insider
Burcak Beser is CTO Division of Oncotelic Therapeutics
| Phone | 650 635 7000 |
| Web | https://www.oncotelic.com |
Oncotelic Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1323) % which means that it has lost $0.1323 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4967 %, meaning that it created $0.4967 on every $100 dollars invested by stockholders. Oncotelic Therapeutics' management efficiency ratios could be used to measure how well Oncotelic Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Oncotelic Therapeutics currently holds 9.8 M in liabilities with Debt to Equity (D/E) ratio of 0.4, which is about average as compared to similar companies. Oncotelic Therapeutics has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncotelic Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Oncotelic Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncotelic Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncotelic to invest in growth at high rates of return. When we think about Oncotelic Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jeroen Beek | Allovir | 60 | |
| Diana MD | Allovir | 53 | |
| Kyung NamWortman | Cellectis SA | 53 | |
| Robert Floyd | Processa Pharmaceuticals | 68 | |
| Jean Epinat | Cellectis SA | N/A | |
| Pascalyne Wilson | Cellectis SA | N/A | |
| MSc MSc | Cellectis SA | 54 | |
| Ann Leen | Allovir | 48 | |
| Agustin MD | Allovir | 60 | |
| PharmD Young | Processa Pharmaceuticals | 72 | |
| PharmD Bigora | Processa Pharmaceuticals | 65 | |
| Dr MBA | Cellectis SA | 46 | |
| Brett Hagen | Allovir | 52 | |
| Valerie Cros | Cellectis SA | N/A | |
| Dana MBA | Allovir | 48 | |
| Daniel Ryweck | Silo Pharma | 59 | |
Management Performance
| Return On Equity | 0.5 | ||||
| Return On Asset | -0.13 |
Oncotelic Therapeutics Leadership Team
Elected by the shareholders, the Oncotelic Therapeutics' board of directors comprises two types of representatives: Oncotelic Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncotelic. The board's role is to monitor Oncotelic Therapeutics' management team and ensure that shareholders' interests are well served. Oncotelic Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncotelic Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vuong Trieu, Chairman CEO | ||
| Seymour MD, Chief Officer | ||
| Larn Hwang, Chief Officer | ||
| Chulho Park, Consultant | ||
| Burcak Beser, CTO Division | ||
| III BA, Chief Director | ||
| Amit Shah, Chief Officer | ||
| Saranjit Saund, CBO Division |
Oncotelic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Oncotelic Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.5 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 31.34 M | ||||
| Shares Outstanding | 391.11 M | ||||
| Shares Owned By Insiders | 55.93 % | ||||
| Number Of Shares Shorted | 662.75 K | ||||
| Price To Earning | 2.16 X | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 8.40 X | ||||
| Gross Profit | 1.74 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Oncotelic OTC Stock
If you are still planning to invest in Oncotelic Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncotelic Therapeutics' history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Stocks Directory Find actively traded stocks across global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |